Previous Close | 0.8890 |
Open | 0.8800 |
Bid | 0.9000 x 1200 |
Ask | 0.9200 x 1000 |
Day's Range | 0.8712 - 0.9254 |
52 Week Range | 0.8000 - 3.8400 |
Volume | |
Avg. Volume | 100,719 |
Market Cap | 40.863M |
Beta (5Y Monthly) | 1.43 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4640 |
Earnings Date | Feb 07, 2022 - Feb 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.02 |
Company to Host Conference Call Today at 1:00pm ETLAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational results for the first quarter ended June 30, 2022. Recent Highlights The Company is preparing the GTX-104 PK bridging study results for submission to the U.S
Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, August 11, 2022, to discuss the Company’s corporate progress and other developments, as well as financial results for first quarter 2023 ended June 30, 2022. The conference call will be available via telephone by diali
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug bupivacaine in 48 healthy subjects. Feedback from FDA was obtained on the study protocol, and the non-objection letter was received on July 12th from Health Canada. The First-Subject, First-Dose was a